Multiple endocrine neoplasia type 2 other imaging findings
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 other imaging findings On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 other imaging findings |
|
FDA on Multiple endocrine neoplasia type 2 other imaging findings |
|
CDC on Multiple endocrine neoplasia type 2 other imaging findings |
|
Multiple endocrine neoplasia type 2 other imaging findings in the news |
|
Blogs on Multiple endocrine neoplasia type 2 other imaging findings |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Other imaging studies for multiple endocrine neoplasia type 2 include fluoro-di-glucose-PET, [18F]-fluorodopamine ([18F]DA) PET, and 99mTc-sestamibi scintigraphy.
Other Imaging Studies
Medullary Thyroid Carcinoma
- Radioactive iodine: lesions do not concentrate radioactive iodine since the tumour does not arise from thyroid follicular cells.
- FDG-PET: avid uptake
- Tl-201: It has been shown to concentrate Thallium-201[1]
- I-123 MIBG: 30% of MTCs show uptake if the thyroid is blocked with Lugol solution prior to the scan
Pheochromocytoma
- [18F]-fluorodopamine ([18F]DA) PET is the best imaging modality for pheochromocytoma
I-123 MIBG (metaiodobenzylguanidine)
- MIBG (123I- or 131I- metaiodobenzylguanidine) scintigraphy is another imaging modality for pheochromocytoma
Octreotide (somatostatin) scans
- Over 70% of tumours express somatostatin receptors. Imaging is obtained 4 hours (+/- 24/48 hours) after an intravenous infusion. Unfortunately the kidney also has somatostatin receptors, as do areas of inflammation, mammary glands, liver, spleen, bowel, gallbladder, thyroid gland and salivary glands. As such interpretation can be difficult.[2]
- Octreotide is usually labeled with either 111In-DTPA (Octreoscan) or (less commonly)123I-Tyr3-DTPA.
PET
- 18F Dopa PET is thought to be highly sensitive according to initial results[3]
Parathyroid Carcinoma
- 99mTc-sestamibi scintigraphy is a good imaging modality for hyperparathyroidism.
![Case courtesy of Dr Hani Al Salam, [4]](/index.php/File:Nuclear_medicine.jpg)
![Case courtesy of Dr Roberto Schubert, [5]](/index.php/File:Nuclear_medicine_02.jpg)
Reference
- ↑ Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH (1985). "Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy". Surgery. 98 (6): 1189–96. PMID 2866591.
- ↑ Pacak, Karel (2007). Pheochromocytoma diagnosis, localization, and treatment. Malden, MA Oxford: Blackwell Pub. ISBN 1405149507.
- ↑ Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I; et al. (2002). "Pheochromocytomas: detection with 18F DOPA whole body PET--initial results." Radiology. 222 (2): 507–12. doi:10.1148/radiol.2222010622. PMID 11818620.
- ↑ "http://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="http://radiopaedia.org/cases/7932">rID: 7932
- ↑ "http://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="http://radiopaedia.org/cases/16148">rID: 16148